Merck & Co., Inc. (NYSE:MRK) Raised to Overweight at Morgan Stanley

Key Points

• Morgan Stanley upgraded Merck to “overweight” and raised its price target from $116 to $179, implying 17.6% upside from the prior close.
• Analyst sentiment remains generally positive, with 16 Buy and seven Hold ratings producing a “Moderate Buy” consensus and an average price target of $138.80.
• Merck and Moderna reported positive late-stage results for their personalized melanoma vaccine combined with Keytruda, strengthening Merck’s oncology pipeline and potentially helping offset Keytruda’s expected patent expiration later this decade.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) was upgraded by Morgan Stanley from an "equal weight" rating to an "overweight" rating in a research note issued on Thursday,Benzinga reports. The firm currently has a $179.00 price target on the stock, up from their previous price target of $116.00. Morgan Stanley's price objective would suggest a potential upside of 17.60% from the company's previous close.

Several other equities research analysts have also issued reports on the stock. Wall Street Zen lowered shares of Merck & Co., Inc. from a "buy" rating to a "hold" rating in a research note on Monday, July 20th. Jefferies Financial Group cut Merck & Co., Inc. from a "strong-buy" rating to a "hold" rating in a report on Wednesday. CICC Research assumed coverage on Merck & Co., Inc. in a report on Wednesday, June 24th. They issued an "outperform" rating and a $138.00 price target for the company. Wells Fargo & Company raised their price objective on Merck & Co., Inc. from $145.00 to $150.00 and gave the company an "overweight" rating in a report on Wednesday, July 8th. Finally, JPMorgan Chase & Co. boosted their price objective on Merck & Co., Inc. from $135.00 to $140.00 and gave the company an "overweight" rating in a research report on Monday, July 13th. Sixteen investment analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the company's stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $138.80.

Merck & Co., Inc. Price Performance

NYSE:MRK opened at $152.21 on Thursday. The company has a debt-to-equity ratio of 1.22, a current ratio of 1.32 and a quick ratio of 1.10. The company has a 50 day moving average price of $126.86 and a 200-day moving average price of $120.74. Merck & Co., Inc. has a 1-year low of $77.58 and a 1-year high of $153.50. The firm has a market cap of $375.53 billion, a price-to-earnings ratio of 121.77, a price-to-earnings-growth ratio of 5.83 and a beta of 0.19.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) last announced its quarterly earnings results on Tuesday, August 4th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.26) by $0.13. Merck & Co., Inc. had a net margin of 4.77% and a return on equity of 16.73%. The firm had revenue of $16.61 billion for the quarter, compared to the consensus estimate of $16.37 billion. During the same period in the prior year, the firm posted $2.13 earnings per share. The firm's quarterly revenue was up 5.1% compared to the same quarter last year. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. Equities research analysts forecast that Merck & Co., Inc. will post 2.77 EPS for the current year.

Insider Transactions at Merck & Co., Inc.

In related news, EVP Chirfi Guindo sold 15,000 shares of the firm's stock in a transaction dated Thursday, August 6th. The shares were sold at an average price of $131.00, for a total value of $1,965,000.00. Following the transaction, the executive vice president directly owned 46,613 shares of the company's stock, valued at approximately $6,106,303. This trade represents a 24.35% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Jennifer Zachary sold 80,315 shares of the business's stock in a transaction that occurred on Wednesday, August 12th. The stock was sold at an average price of $133.46, for a total value of $10,718,839.90. Following the sale, the executive vice president owned 45,509 shares of the company's stock, valued at approximately $6,073,631.14. This trade represents a 63.83% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 228,238 shares of company stock worth $29,977,783 in the last three months. 0.17% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the company. Susquehanna Fundamental Investments LLC purchased a new stake in Merck & Co., Inc. during the 2nd quarter valued at about $11,470,000. Benjamin Edwards Inc. lifted its stake in Merck & Co., Inc. by 36.3% in the 2nd quarter. Benjamin Edwards Inc. now owns 224,529 shares of the company's stock worth $28,854,000 after purchasing an additional 59,854 shares in the last quarter. Alyeska Investment Group L.P. lifted its stake in Merck & Co., Inc. by 7.6% in the 2nd quarter. Alyeska Investment Group L.P. now owns 2,480,590 shares of the company's stock worth $318,756,000 after purchasing an additional 175,016 shares in the last quarter. Meiji Yasuda Life Insurance Co boosted its holdings in shares of Merck & Co., Inc. by 4.1% during the 2nd quarter. Meiji Yasuda Life Insurance Co now owns 14,833 shares of the company's stock worth $1,906,000 after purchasing an additional 590 shares during the last quarter. Finally, Thornburg Investment Management Inc. grew its position in shares of Merck & Co., Inc. by 1.6% in the second quarter. Thornburg Investment Management Inc. now owns 3,787,976 shares of the company's stock valued at $486,755,000 after purchasing an additional 59,303 shares in the last quarter. 76.07% of the stock is owned by institutional investors and hedge funds.

Merck & Co., Inc. News Roundup

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: The combination of Moderna’s individualized vaccine, intismeran, and Keytruda significantly extended the time high-risk melanoma patients remained free of recurrence and reduced the risk of cancer spreading compared with Keytruda alone. The result is viewed as the first positive late-stage validation of a personalized mRNA cancer vaccine. Merck, Moderna say melanoma skin cancer vaccine meets goals in large trial
• Positive Sentiment: The data strengthen Merck’s oncology pipeline and could help offset concerns about the expected expiration of Keytruda’s patent later this decade. The companies are also studying similar vaccine approaches in lung, pancreatic, breast and other cancers, potentially expanding the commercial opportunity if regulators approve the treatment; approval is targeted for 2027. Moderna, Merck breakthrough could usher in wave of cancer vaccines
• Positive Sentiment: Investor enthusiasm was reflected in unusually heavy options activity, with 68,587 Merck call options purchased—about 188% above typical daily volume—suggesting increased bullish speculation, though options activity is not a fundamental performance measure.
• Neutral Sentiment: Broader bond-market relief supported interest-rate-sensitive equities and healthcare stocks, providing a favorable market backdrop for MRK. Stock Market Today, Aug. 19
• Negative Sentiment: Jefferies downgraded MRK from “strong buy” to “hold.” The call could limit further upside and reflects a more cautious analyst view after the stock’s strong run toward its 52-week high, although the firm’s specific rationale was not provided.

About Merck & Co., Inc.

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source